Piramal REF: PHL-PV-HU-SOP-100013

Version 6.0

Suspected Adverse Event Report Form (Human)

 

 

 

 

I consent to Piramal's use of this data to respond to my complaint. Any and all information collected will be kept secure and will not be sold, rented, loaned, or otherwise disclosed to anyone
except to the drug regulatory agency to comply with regulatory obligations for monitoring of drug safety profile throughout life cycle of medicinal product. For more details regarding privacy
policy, refer http://www. piramalcriticalcare.com/privacy-policy/ or write to us at dpo.criticalcare@piramal.com.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1. Patient Data: 2. Report: Select date
Initials mae of Birth/ Gender: Height Weight Ethnicity eal Follow-up Final
Female ~
S mente dys ae wm 175 (cm/in)| 75 (kg/Ib) H
No
3. Patient’s Relevant Medical/ Surgical/ Drug/ Family history (use a separate page, if needed):
Sr. No. |Condition/ Procedure/ Drug Start date Stop date |Comments, if any
1. Drug 231 Select date Select date None
Dx Drug 619 Select date Select date None
3. Drug 718 Select date Select date None
4. Paracetomol Select date Select date None
5. Cipla Select date Select date None
6. Dolo 650 Select date Select date None
4. Suspected Pharmaceutical Products (use a separate page, if needed):
Brand Name (Generic a Batch Number Route of ‘ Dose & Start Date/ Stop Date/
Name) Manufacturer Indication & Expiry Date Administratio Frequency Time Time
Dolo 650 Jay Industries No 32 & 22/12/19 Yes Daily Select date & Select date &

 

 

 

PHL-PV-HU-TP-100003, V2.0

Confidential and Proprietary
The contents of this document are confidential and proprietary information of Piramal Enterprises Ltd. The unauthorized use, disclosure or reproduction is strictly

prohibited.

Page 1 of 36 Piramal

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REF: PHL-PV-HU-SOP-100013
Version 6.0
time time
Select date & Select date &
time time
Select date & Select date &
time time
Select date & Select date &
time time
Use according to label Unknown Yes No Explain
Previous Exposure and Reaction(s) to Primary suspect product: Yes No

 

 

If yes, describe with AE, if any:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5. Concomitant Medication Details (Give the list of the other medicinal products used concurrently, use separate page if needed):
Brand Name Indication Ponty Liaba. & Ad te of on Fraauandy Start Date Stop Date
Select date Select date
Select date Select date
Select date Select date
Select date Select date
Select date Select date
Select date Select date

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6. Adverse Event (AE) Data (For all adverse event(s) reported following administration of suspect product):

Adverse Event Serious (For Start Date/ Time 2 Stop Date/ Time Outcome Suspect Comments: (write
Yes, choose 3 drug/s reason with contributory
the criteria) a factors)

°
cheese a Select date & time Select date & time MHIEOSS ai
item. item.
Ec e Ct sea
Choose an Select date & time Select date & time sulgese an
item. item.
Choose an Select date & time Select date & time Choose an
PHL-PV-HU-TP-100003, V2.0 Confidential and Proprietary Page 2 of 46 Piramal REF: PHL-PV-HU-SOP-100013

 

 

 

 

 

 

 

 

 

 

 

 

Version 6.0
item. item.
enp0se an Select date & time Select date & time spe an
item. item.
Choose an Choose an
“ Select date & time Select date & time
item. item.

 

 

 

 

 

 

 

If multiple suspect drug then write the

drug name with causality in comments
section

Action taken with Suspect product after adverse event Did event abate after stopping

drug?/ De-challenge
Withdrawn/ Permanently stopped Yes

Did event reappear after
reintroduction?/ Re-challenge

 

 

 

Temporarily held

 

 

 

 

Yes

 

 

 

No change

 

 

 

Dose reduced No

 

 

 

No

 

 

 

 

 

 

 

 

Dose reduced

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Not Applicable/Unknown Not App Not Applicable
Yes
For fatal outcome, was a Post-Mortem/Autopsy NA No Autopsy report/death certificate available
performed?
No Yes (Please Attach)
How was the adverse event treated? No treatment —
Prescription drug [_], Please give details
Other
If the patient was enrolled in any clinical study, specify | Protocol No.:
Patient no.:
No
Has this case been reported to Regulatory Authority?
Yes Reference Number:

 

 

 

 

 

 

 

 

10.

 

Reporter’s details

 

 

Patient’s treating Physician details (if reporter is not the
physician)

 

 

 

PHL-PV-HU-TP-100003, V2.0 Confidential and Proprietary Page 3 of 4Version 6.0

6 Piramal REF: PHL-PV-HU-SOP-100013

 

 

Name:

 

Occupation

 

Address:

 

Tel. No:

 

Email:

 

 

 

 

 

Signature:

 

*Note: Template can be edited as per requirements.

 

PHL-PV-HU-TP-100003, V2.0 Confidential and Proprietary Page 40f 4